Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 5,765 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Refractory Malignancy Clear all

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more

Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
Interventions: AZD4573; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more

Conditions: Gastro-Oesophageal Cancer
Interventions: Regorafenib, Placebo; Drug · Other
Lead sponsor: Australasian Gastro-Intestinal Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: fludarabine phosphate, triapine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Houston, Texas

Conditions: Bladder Cancer
Interventions: SCH 721015; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Enasidenib, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Buffalo, New York • East Hills, New York

Conditions: Renal Cell Carcinoma
Interventions: Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250, Positron emission tomography/computed tomography, Protein expression analysis, Immunohistochemistry; Drug · Genetic · Other + 1 more
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: thalidomide; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Ewing Sarcoma
Interventions: LX-101; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
Interventions: Elranatamab, Tocilizumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Denver, Colorado • Columbia, Maryland • Las Vegas, Nevada + 2 more

Conditions: Acute Myeloid Leukaemia
Interventions: SAR445419, fludarabine, cytarabine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Omaha, Nebraska • The Bronx, New York • Houston, Texas

Conditions: Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions: AZD5153, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Cancer
Interventions: Morphine, Oxcarbazepine; Drug
Lead sponsor: Costantine Albany; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Pharmacokinetic Study; Other · Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Newport Beach, California

Conditions: Terminally Ill, Histologically-confirmed Advanced Cancer, Pain, Intractable
Interventions: Substance P-Saporin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: La Jolla, California • Dallas, Texas

Conditions: Sarcoma
Interventions: Trabectedin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 15 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more

Conditions: Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: assessment of therapy complications; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years
Enrollment: 3,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 451
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more

Conditions: Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: cixutumumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Months to 30 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 93
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: GEM 231, docetaxel; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Kidney Cancer
Interventions: Carfilzomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 93
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
Interventions: 131-I Apamistamab, CAR T-cell; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
Interventions: [18F]FES; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Brivanib Metastatic Renal Cell Carcinoma

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

FID-007 in Treating Participants With Advanced Solid Tumors

A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

[18F]FES PET/CT in Endocrine Refractory Breast Cancer